Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Senate committee advances HB712 with transparency reporting for 340B revenues; pharma seeks amendments
Summary
The committee passed HB712 with amendments that add transparency and reporting requirements for 340B program revenues used by safety-net providers. Testimony split between hospitals and pharmaceutical industry representatives; committee opted for reporting requirements rather than a full audit mandate.
The Senate Committee on Health and Human Services voted March 19 to advance House Bill 712 with amendments that increase transparency around 340B drug-discount revenues used by safety‑net providers.
Why it matters: The 340B Drug Pricing Program enables eligible health providers to buy outpatient drugs at discounted prices; revenues from those discounts often support services for low‑income patients. Hospitals, Federally Qualified Health Centers (FQHCs) and native Hawaiian health centers told the committee those revenues fund transportation, chronic‑disease programs and specialty services. Pharmaceutical industry groups urged caution and asked for…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
